TY  - JOUR
A1  - Astori, Giuseppe
A1  - Amati, Eliana
A1  - Bambi, Franco
A1  - Bernardi, Martina
A1  - Chieregato, Katia
A1  - Schäfer, Richard
A1  - Sella, Sabrina
A1  - Rodeghiero, Francesco
T1  - Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells : present and future
T2  - Stem cell research & therapy
N2  - The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing-thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.
KW  - Platelet lysate
KW  - Platelet releasate
KW  - Mesenchymal stem/stromal cells
KW  - Fetal bovine serum
KW  - Pathogen reduction
KW  - Manufacturing
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/43167
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-431675
SN  - 1757-6512
N1  - Copyright: © The Author(s). 2016. Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
VL  - 7
IS  - 1, Art. 93
SP  - 1
EP  - 8
PB  - BioMed Central
CY  - London
ER  -